<article id="sc_page05" class="slide" data-ag-slide-name="sc_page05">
    <div class="basic">
      <h1 data-ag-editable="Main Title">Neulasta<sup>®</sup> reduces the incidence of FN across all chemotherapy cycles</h1>
        <div id="sc-pop-up05" class="sc-pop-up"></div>
        <!-- Content here -->

        <h4 data-ag-editable="Subtitle" id="sub-title">Breast cancer</h4>

        <ul id="list">
            <li>Primary endpoint: Neulasta<sup>®</sup> and daily G-CSF had a similar mean duration of grade 4 neutropenia in cycle 1<sup>[Holmes 2002, Green 2003]</sup></li>
            <li>Secondary endpoint: Data suggest that Neulasta<sup>®</sup> reduced the incidence of FN across all cycles to a greater extent than daily G-CSF<sup>[Holmes 2002, Green 2003]</sup></li>
        </ul>



        <div id="sc_page_05_graph2_holder" class="main_content_style">
            <img src="content/images/sc_page05/graph.png" width="500" height="260" data-ag-editable="  Graph 2 Background">
            <div id="cooper_2011_graph2_content">
                <h2 id="graph2_title_sc_page_05" data-ag-editable="  Graph 2 Title">Incidence of FN on all cycles (4 cycles) </h2>
                <p id="graph2_legend1_sc_page_05" data-ag-editable="  Graph 2 Legend 1">Holmes study (n=296)<br/>P=0.029</p>
                <p id="graph2_legend2_sc_page_05" data-ag-editable="  Graph 2 Legend 2">Green Study (n=152)<br/>P=NS</p>
                <p id="sc_page05_first_footer_label" data-ag-editable="  footer label1">Filgrastim<br/>n=147</p>
                <p id="sc_page05_second_footer_label" data-ag-editable="  footer label1">Neulasta<sup>®</sup><br/>n=149</p>
                <p id="sc_page05_third_footer_label" data-ag-editable="  footer label1">Filgrastim<br/>n=75</p>
                <p id="sc_page05_fourth_footer_label" data-ag-editable="  footer label1">Neulasta<sup>®</sup><br/>n=77</p>
                <p id="graph2_vertical_axis_title_sc_page_05" data-ag-editable="  Graph 2 Vertical Axis Title">Incidence of FN (%) </p>
                <ul id="sc_page_05_graph2_vertical_axis_value" data-ag-editable="  Graph 2 Vertical Axis Values">
                    <li>25</li>
                    <li>20</li>
                    <li>15</li>
                    <li>10</li>
                    <li>5</li>
                    <li>0</li>
                </ul>
                <p id="graph2_bottom_text_sc_page_05" data-ag-editable="  Graph 2 Bottom Text">Adapted from Holmes FA <i>et al.</i> J Clin Oncol 2002; 20(3):727-31 and Green MD <i>et al.</i> Ann Oncol 2003; 14(1):29-35</p>

            </div>
            <div id="sc_page_05_graph2_arrow1" style="height: 177px;">
                <img src="content/images/carer_pages/neulasta_efficacy/ne_page1_graph2_data1.png" width="301" height="270" data-ag-editable="  Graph 2 Left Bar">
                <p id="sc_page_05_graph2_bar1_text" data-ag-editable="  Graph 2 Bar 1 Value"><span>18%</span></p>
            </div>

            <div id="sc_page_05_graph2_arrow3" style="height: 87px;">
                <img src="content/images/carer_pages/neulasta_efficacy/ne_page1_graph2_data3.png" width="205" height="207" data-ag-editable="  Graph 2 Right Arrow">
                <p id="sc_page_05_graph2_bar3_text" data-ag-editable="  Graph 2 Bar 3 Value"><span>9%</span></p>
            </div>
            <!---SECOND COUPLE OF GRAPH --->
            <div id="sc_page_05_graph2_arrow1-2" style="height: 195px;">
                <img src="content/images/carer_pages/neulasta_efficacy/ne_page1_graph2_data1.png" width="301" height="270" data-ag-editable="  Graph 2 Left Bar">
                <p id="sc_page_05_graph2_bar1_text-2" data-ag-editable="  Graph 2 Bar 1 Value"><span>20%</span></p>
            </div>

            <div id="sc_page_05_graph2_arrow3-2" style="height: 121px;">
                <img src="content/images/carer_pages/neulasta_efficacy/ne_page1_graph2_data3.png" width="205" height="207" data-ag-editable="  Graph 2 Right Arrow">
                <p id="sc_page_05_graph2_bar3_text-2" data-ag-editable="  Graph 2 Bar 3 Value"><span>13%</span></p>
            </div>
            <!---END SECOND COUPLE OF GRAPH --->


        </div>
        <p id="footer-copy" >P values are unadjusted p values of explorative tests on differences between treatments.</p>
    </div>

    </div>
    <!-- Reference Information Starts -->
    <div class="lightbox_data" id="sc_page05_refs">
       <div class="main_content_style">
          <p><strong data-ag-editable="References Title">References:</strong></p>
          <br />
          <div data-ag-editable="References List">
             <ol>
                 <li>Holmes FA <i>et al.</i> Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002; 20(3):727-731</li>
                 <li>Green MD <i>et al.</i> A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003; 14(1):29-35</li>
             </ol>
          </div>
          <p data-ag-editable="References Bottom Copy"></p>
       </div>
    </div>
    <!-- Reference Information Ends -->
</article>